Given the exceptional importance of HER2 for treating breast cancer, we performed proof-of-principle experiments to show that combined pharmacological inhibition of HER2 and TRPM7 elicits synergistic antiproliferative effects on HER2-positive breast cancer cells. The gene discussed is ERBB2; the disease is breast carcinoma.